2024
52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Gordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, Pinto J, Gisondi P. 52671 Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials. Journal Of The American Academy Of Dermatology 2024, 91: ab145. DOI: 10.1016/j.jaad.2024.07.577.Peer-Reviewed Original Research52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA
Sicco K, Soung J, Strober B, Irvine A, Wajsbrot D, Gromek K, Wolk R, Barnes D, Takiya L. 52875 Integrated cardiovascular safety analysis of ritlecitinib in patients with alopecia areata (AA) in the phase 2 and phase 3 ALLEGRO clinical trials, and contextualization with a US cohort of patients with AA. Journal Of The American Academy Of Dermatology 2024, 91: ab55. DOI: 10.1016/j.jaad.2024.07.228.Peer-Reviewed Original Research52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
Strober B, Krueger J, Magnolo N, Vender R, Boehncke W, Hong H, Tilt N, Staelens F, Wiegratz S, Paul C. 52675 Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials. Journal Of The American Academy Of Dermatology 2024, 91: ab142. DOI: 10.1016/j.jaad.2024.07.572.Peer-Reviewed Original ResearchBimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials
Gordon K, Thaçi D, Gooderham M, Okubo Y, Strober B, Peterson L, Deherder D, López Pinto J, Gisondi P. Bimekizumab Safety and Tolerability in Moderate to Severe Plaque Psoriasis: Pooled Analysis from Up to 4 Years of Treatment in 5 Phase 3/3b Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2024, 8: s404. DOI: 10.25251/skin.8.supp.404.Peer-Reviewed Original ResearchTreatment-emergent adverse eventsSevere plaque psoriasisOpen-label extensionPlaque psoriasisOral candidiasisPatient yrModerate to severe plaque psoriasisUpper respiratory tract infectionLong-term safety of treatmentRespiratory tract infectionsNext scheduled visitYear of treatmentSafety of treatmentLong-term safetySafety findingsTract infectionsLong-term managementBimekizumabSafety profileAdverse eventsPooled analysisClinical trialsQ8WSafety dataPsoriasisBrodalumab: 5-Year US Pharmacovigilance Report
Lebwohl M, Koo J, Armstrong A, Strober B, Martin G, Rawnsley N, Goehring E, Jacobson A. Brodalumab: 5-Year US Pharmacovigilance Report. Dermatology And Therapy 2024, 14: 1349-1357. PMID: 38724839, PMCID: PMC11116300, DOI: 10.1007/s13555-024-01162-8.Peer-Reviewed Original ResearchAdverse eventsSystemic therapyInterleukin-17 receptor A antagonistPharmacovigilance dataPsoriasis Longitudinal AssessmentMajor adverse cardiovascular eventsLong-term clinical trialsUS prescribing informationAdverse cardiovascular eventsPlaque psoriasisReported malignanciesSafety profileAdult patientsCardiovascular eventsBrodalumabBox warningUS patientsPharmacovigilance reportsFungal infectionsClinical trialsPrescribing informationSafety signalsSuspected COVID-19 casesPatientsPackage insertsMental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials
Blauvelt A, Armstrong A, Merola J, Strober B, de Cuyper D, Peterson L, Davies O, Stark J, Lebwohl M. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials. Journal Of The American Academy Of Dermatology 2024, 91: 72-81. PMID: 38447700, DOI: 10.1016/j.jaad.2024.02.039.Peer-Reviewed Original ResearchModerate to severe psoriasisColumbia-Suicide Severity Rating ScaleSevere psoriasisIncreased risk of suicidal ideationRisk of suicidal ideationModerate to severe plaque psoriasisClinical trialsSeverity Rating ScaleFood and Drug Administration approvalRating scale responsesGeneral psoriasis populationPsoriasis patient populationPatient Health Questionnaire-9Placebo-treated patientsSevere plaque psoriasisMental health outcomesMental health changesPhase 2/3 trialsEuropean Medicines Agency approvalInterleukin (IL)-17ADrug Administration approvalPatient Health Questionnaire-9 scoresSuicidal ideationMeasure depressionRating ScaleMeaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary
Papp K, Gordon K, Strober B, Zhuo J, Becker B, Zhong Y, Beaumont J, Pham T, Kisa R, Napoli A, Banerjee S, Armstrong A. Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary. JAMA Dermatology 2024, 160: 204-209. PMID: 38117487, PMCID: PMC10733845, DOI: 10.1001/jamadermatol.2023.5058.Peer-Reviewed Original ResearchSevere plaque psoriasisPatient Global ImpressionClinical trialsPsoriasis symptomsScore changeSigns DiaryPlaque psoriasisGlobal ImpressionWeek 16MAIN OUTCOMEPatient-reported end pointsPlacebo-controlled phase 3 clinical trialPhase 3 clinical trialsPatient-reported assessmentsPhase 3 programMeaningful change thresholdCategory improvementDisease burdenMeaningful score changesSelective TYK2 inhibitorsPatient changeBaseline scoresPsoriasisPatientsEnd point
2023
41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials
Armstrong A, Blauvelt A, Papp K, Green L, Feely M, Malatestinic W, See K, McKean-Matthews M, Strober B. 41602 Achievement of National Psoriasis Foundation (NPF) treatment targets and acceptable responses among patients with psoriasis treated with ixekizumab versus other biologics in head-to- head clinical trials. Journal Of The American Academy Of Dermatology 2023, 89: ab12. DOI: 10.1016/j.jaad.2023.07.056.Peer-Reviewed Original ResearchTreatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary
Armstrong A, Gooderham M, Warren R, Papp K, Strober B, Thaçi D, Morita A, Szepietowski J, Imafuku S, Colston E, Throup J, Kundu S, Schoenfeld S, Linaberry M, Banerjee S, Blauvelt A. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary. Immunotherapy 2023, 15: 963-973. PMID: 37150952, DOI: 10.2217/imt-2023-0061.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisPlaque psoriasisSide effectsNew treatmentsBasic everyday tasksStudy treatment phaseCommon side effectsMonths of treatmentSymptoms of psoriasisPsoriasis plaquesDaily pillPsoriasis treatmentAcceptable safetyClinical trialsPsoriasisTreatment phasePlaceboDeucravacitinibNasal passagesLarger studyApremilastSkin appearanceEmotional distressTreatmentPillsTreatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary
Strober B, Thaçi D, Sofen H, Kircik L, Gordon K, Foley P, Rich P, Paul C, Bagel J, Colston E, Throup J, Kundu S, Sekaran C, Linaberry M, Banerjee S, Papp K. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. Immunotherapy 2023, 15: 787-797. PMID: 37150956, DOI: 10.2217/imt-2023-0062.Peer-Reviewed Original ResearchConceptsSevere plaque psoriasisPlaque psoriasisSide effectsNew treatmentsBasic everyday tasksCommon side effectsMonths of treatmentUndesirable side effectsPatch of skinDaily pillPsoriasis treatmentClinical trialsPlaceboPsoriasisDeucravacitinibLarger studyTreatmentApremilastGreater improvementMore participantsSimilar ratesPillsMedical journalsParticipantsSimilar number
2022
Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials
Blauvelt A, Stein Gold L, Gooderham M, Strober B, Pinter A, Carrascosa J, Gisondi P, Bleier J, Madden C, Deherder D, Gomez N, Warren R. Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. SKIN The Journal Of Cutaneous Medicine 2022, 6: s67. DOI: 10.25251/skin.6.supp.67.Peer-Reviewed Original Research
2021
27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials
Strober B, Papp K, Blauvelt A, Lebwohl M, Wu J, Deherder D, Madden C, Wixted K, Wang M, Augustin M. 27505 Bimekizumab short-term and longer-term anxiety, depression, and suicidal ideation/behavior in patients with moderate to severe plaque psoriasis: Analysis of pooled data from eight phase 2/3 clinical trials. Journal Of The American Academy Of Dermatology 2021, 85: ab149. DOI: 10.1016/j.jaad.2021.06.611.Peer-Reviewed Original ResearchThe Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score
Papp K, Lebwohl M, Kircik L, Pariser D, Strober B, Krueger G, Berk D, Navale L, Higham R. The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. Dermatology And Therapy 2021, 11: 1079-1083. PMID: 34236691, PMCID: PMC8322185, DOI: 10.1007/s13555-021-00572-2.Peer-Reviewed Original ResearchPOS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Mease P, Lertratanakul A, Strober B, Tsuji S, Richette P, Lovan C, Feng D, Anderson J, Van den Bosch F. POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Annals Of The Rheumatic Diseases 2021, 80: 788-789. DOI: 10.1136/annrheumdis-2021-eular.564.Peer-Reviewed Original ResearchMinimal disease activityBiologic DMARDsOverall study populationInadequate responseAbbVie Inc.Boehringer IngelheimSpeakers bureauClinical trialsStudy populationEli LillyConsistent efficacyBristol-MyersFirst-line anti-TNF therapyDisease-modifying anti-rheumatic drugsSF-36 physical component summaryAnti-TNF therapyComprehensive disease controlPrior inadequate responseSubgroups of ptsThird-line therapyAnti-rheumatic drugsInvestigator's Global AssessmentSanofi-AventisPhysical component summaryConfidence intervalsBimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials
Reich K, Blauvelt A, Lebwohl M, Papp K, Rich P, Strober B, De Cuyper D, Madden C, Peterson L, Vanvoorden V, Warren R. Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials. SKIN The Journal Of Cutaneous Medicine 2021, 5: s21. DOI: 10.25251/skin.5.supp.21.Peer-Reviewed Original Research
2020
15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials
Reich K, Strober B, Langley R, Song M, Shen Y, You Y, Foley P, Blauvelt A. 15280 Characterization of super responders to guselkumab treatment in moderate to severe psoriasis: Results from the VOYAGE 1 and 2 clinical trials. Journal Of The American Academy Of Dermatology 2020, 83: ab145. DOI: 10.1016/j.jaad.2020.06.668.Peer-Reviewed Original Research
2019
Hidradenitis suppurativa Current and emerging treatments
Goldburg S, Strober B, Payette M. Hidradenitis suppurativa Current and emerging treatments. Journal Of The American Academy Of Dermatology 2019, 82: 1061-1082. PMID: 31604100, DOI: 10.1016/j.jaad.2019.08.089.Peer-Reviewed Original ResearchConceptsHidradenitis suppurativaPathogenesis of HSNumerous clinical trialsPotential therapeutic roleMedical education seriesAnticytokine therapyTreatment optionsHS pathogenesisClinical trialsTherapeutic roleNovel therapiesNew therapiesTherapyPathogenesisEducation seriesRecent studiesTreatmentSuppurativaSurgeryCytokinesEtiologyTrialsApremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study
Strober B, Alikhan A, Lockshin B, Shi R, Cirulli J, Schafer P. Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study. Journal Of Dermatological Science 2019, 96: 126-133. PMID: 31787506, DOI: 10.1016/j.jdermsci.2019.09.003.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisIL-17APlaque psoriasisIL-22Week 16T cellsRegulatory T cell numbersT helper 17 (Th17) cellsEfficacy of apremilastIL-23 levelsTotal T cellsPlasma cytokine levelsRegulatory T cellsT cell numbersMedian percentage reductionPathogenesis of psoriasisSevere psoriasisCardiometabolic biomarkersClinical improvementCytokine levelsInflammatory biomarkersIL-17FWeeks 0Clinical trialsWeek 4Tofacitinib benefit‐risk profile in chronic plaque psoriasis
Strober B, Gottlieb A, Kerkhof P, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Tofacitinib benefit‐risk profile in chronic plaque psoriasis. British Journal Of Dermatology 2019, 180: e19-e19. DOI: 10.1111/bjd.17373.Peer-Reviewed Original ResearchBiologic treatmentSevere psoriasisPlaque psoriasisHigh doseChronic plaque psoriasisHerpes zoster infectionSevere plaque psoriasisAcceptable safety profileBenefit-risk profileNew oral drugsZoster infectionPatient yearsTofacitinib treatmentUlcerative colitisPatients' qualityRheumatoid arthritisSafety profileAppearance of skinClinical trialsOral drugsEffective treatmentSide effectsPsoriasisPatientsDrugsLong‐term safety of adalimumab in adult patients with plaque psoriasis
Leonardi C, Papp K, Strober B, Thaçi D, Warren R, Tyring S, Arikan D, Karunaratne M, Valdecantos W. Long‐term safety of adalimumab in adult patients with plaque psoriasis. British Journal Of Dermatology 2019, 180: e13-e13. DOI: 10.1111/bjd.17366.Peer-Reviewed Original ResearchNon-melanoma skin cancerPatient yearsLong-term safetyIncidence of NMSCTumor necrosis factor alphaMost common AEsNew safety signalsUpper respiratory infectionIncidence of malignancyAnalysis of patientsNumber of patientsNecrosis factor alphaDifferent clinical trialsCommon AEsPlaque psoriasisAdult patientsAdverse eventsRespiratory infectionsOpportunistic infectionsSerious infectionsClinical trialsIncidence rateSafety signalsFactor alphaAdalimumab